Tranexamic Acid Injectable Solution — Competitive Intelligence Brief

Tranexamic Acid Injectable Solution (Tranexamic Acid Injectable Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrinolytic agent. Area: Hematology / Hemostasis.

marketed Antifibrinolytic agent Plasminogen / Plasmin Hematology / Hemostasis Small molecule

Target snapshot

Tranexamic Acid Injectable Solution (Tranexamic Acid Injectable Solution) — Mount Sinai Hospital, Canada. Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tranexamic Acid Injectable Solution TARGET	Tranexamic Acid Injectable Solution	Mount Sinai Hospital, Canada	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid (TXA)	Tranexamic Acid (TXA)	NYU Langone Health	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Injectable Product	Tranexamic Acid Injectable Product	The University of Texas Health Science Center at San Antonio	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid plus standard of care	Tranexamic Acid plus standard of care	Pfizer	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Irrigation	Tranexamic Acid Irrigation	University of Wisconsin, Madison	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Dosage 1	Tranexamic Acid Dosage 1	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid / Sodium chloride	Tranexamic Acid / Sodium chloride	University Hospital, Bordeaux	marketed	Antifibrinolytic agent	Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrinolytic agent class)

1. Montefiore Medical Center · 2 drugs in this class
2. Pfizer · 2 drugs in this class
3. Hamilton Health Sciences Corporation · 2 drugs in this class
4. Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
5. Henry Ford Health System · 1 drug in this class
6. Massachusetts General Hospital · 1 drug in this class
7. NYU Langone Health · 1 drug in this class
8. Mount Sinai Hospital, Canada · 1 drug in this class
9. Dr. Lutfi Kirdar Kartal Training and Research Hospital · 1 drug in this class
10. Carlos A Acosta-Olivo · 1 drug in this class